Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


Articles published in Gastroenterology

Retrieve available abstracts of 104 articles:
HTML format
Text format



Single Articles


    July 2018
  1. LUNEMANN S, Schobel A, Kah J, Fittje P, et al
    Interactions Between KIR3DS1 and HLA-F Activate Natural Killer Cells to Control HCV Replication in Cell Culture.
    Gastroenterology. 2018 Jul 19. pii: S0016-5085(18)34785.
    PubMed     Text format     Abstract available


  2. NAHON P, Layese R, Bourcier V, Cagnot C, et al
    Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
    Gastroenterology. 2018 Jul 18. pii: S0016-5085(18)34781.
    PubMed     Text format     Abstract available


    June 2018
  3. ESTEBAN R, Pineda JA, Calleja JL, Casado M, et al
    Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With HCV genotype 3 Infection and Cirrhosis.
    Gastroenterology. 2018 Jun 26. pii: S0016-5085(18)34684.
    PubMed     Text format     Abstract available


    May 2018
  4. GARDINI AC, Conti F, Brillanti S, Andreone P, et al
    Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals.
    Gastroenterology. 2018 May 7. pii: S0016-5085(18)30419.
    PubMed     Text format    


  5. MOORMAN AC, Xing J, Nelson NP
    Need for Increasing Hepatitis A Virus Vaccination Among Patients Infected With Hepatitis B Virus and Hepatitis C Virus.
    Gastroenterology. 2018 May 3. pii: S0016-5085(18)34481.
    PubMed     Text format    


    April 2018
  6. BONACCI M, Lens S, Marino Z, Londono MC, et al
    Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure.
    Gastroenterology. 2018 Apr 26. pii: S0016-5085(18)30485.
    PubMed     Text format     Abstract available


  7. CALVARUSO V, Cabibbo G, Cacciola I, Petta S, et al
    Incidence of Hepatocellular Carcinoma in Patients with HCV-associated Cirrhosis Treated with Direct-Acting Antiviral Agents.
    Gastroenterology. 2018 Apr 12. pii: S0016-5085(18)30441.
    PubMed     Text format     Abstract available


  8. MORSE A, Barritt AS 4th, Jhaveri R
    Individual State Hepatitis C Data Supports Expanding Screening Beyond Baby Boomers to All Adults.
    Gastroenterology. 2018 Apr 2. pii: S0016-5085(18)30304.
    PubMed     Text format    


  9. SCOTT RA, Aithal GP, Francis ST, Irving WL, et al
    Pretreatment Lesions on Magnetic Resonance Imaging in Patients With Hepatitis C Virus Infection Diagnosed With Hepatocellular Carcinoma After Initiating Direct-Acting Antiviral Therapy.
    Gastroenterology. 2018 Apr 2. pii: S0016-5085(18)30305.
    PubMed     Text format    


    March 2018
  10. GRUNVOGEL O, Colasanti O, Lee JY, Kloss V, et al
    Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll Like Receptor 3 in Hepatocytes.
    Gastroenterology. 2018 Mar 10. pii: S0016-5085(18)30309.
    PubMed     Text format     Abstract available


  11. EL-SHERIF O, Jiang ZG, Tapper EB, Huang KC, et al
    Baseline Factors Associated with Improvements in Decompensated Cirrhosis After Direct-acting Antiviral Therapy for HCV Infection.
    Gastroenterology. 2018 Mar 10. pii: S0016-5085(18)30314.
    PubMed     Text format     Abstract available


  12. PONZETTO A, Figura N
    Risk of Hepatocellular Carcinoma After Cure of Hepatitis C Virus.
    Gastroenterology. 2018 Mar 8. pii: S0016-5085(18)30153.
    PubMed     Text format    


  13. LO GH
    The Elevation of Hepatic Venous Pressure Gradient After Sustained Virologic Response in Hepatitis C Virus-Related Cirrhosis.
    Gastroenterology. 2018 Mar 8. pii: S0016-5085(18)30148.
    PubMed     Text format    


  14. MANDORFER M, Reiberger T, Peck-Radosavljevic M
    Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response.
    Gastroenterology. 2018 Mar 8. pii: S0016-5085(18)30150.
    PubMed     Text format    


    February 2018
  15. PHAM LV, Ramirez S, Gottwein JM, Fahnoe U, et al
    HCV Genotype 6a Escape from and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
    Gastroenterology. 2018 Feb 15. pii: S0016-5085(18)30212.
    PubMed     Text format     Abstract available


  16. TEDESCO D, Thapa M, Chin CY, Ge Y, et al
    Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic gammadelta T-cell Receptor-positive Cells and Pathogenesis of Cholestatic Liver Disease.
    Gastroenterology. 2018 Feb 15. pii: S0016-5085(18)30214.
    PubMed     Text format     Abstract available


  17. MA AT, Feld JJ
    Hepatitis B Reactivation With Hepatitis C Treatment: Bringing Some Clarity to the Black Box.
    Gastroenterology. 2018 Feb 6. pii: S0016-5085(18)30161.
    PubMed     Text format    


  18. TAVIS JE, Lomonosova E
    NVR 3-778 Plus Pegylated Interferon-alpha Treatment for Chronic Hepatitis B Viral Infections: Could 1 + 1 = 3?
    Gastroenterology. 2018;154:481-482.
    PubMed     Text format    


    January 2018
  19. MUTZ P, Metz P, Lempp FA, Bender S, et al
    HBV Bypasses the Innate Immune Response and Does not Protect HCV From Antiviral Activity of Interferon.
    Gastroenterology. 2018 Jan 31. pii: S0016-5085(18)30112.
    PubMed     Text format     Abstract available


  20. AGHEMO A, Colombo M
    Glecaprevir/Pibrentasvir: The Final Piece in the Hepatitis C Virus Treatment Puzzle?
    Gastroenterology. 2018 Jan 31. pii: S0016-5085(18)30100.
    PubMed     Text format    


  21. YOSHIKAWA T, Ohana M, Fukuda A
    High fever after radiofrequency ablation of hepatocellular carcinoma.
    Gastroenterology. 2018 Jan 31. pii: S0016-5085(18)30134.
    PubMed     Text format    


  22. MOORMAN AC, Xing J, Rupp LB, Gordon SC, et al
    Hepatitis B Virus Infection and Hepatitis C Virus Treatment in a Large Cohort of Hepatitis C-Infected Patients in the United States.
    Gastroenterology. 2018 Jan 19. pii: S0016-5085(17)36689.
    PubMed     Text format    


    December 2017
  23. GOTTWEIN JM, Pham LV, Mikkelsen LS, Ghanem L, et al
    Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.
    Gastroenterology. 2017 Dec 21. pii: S0016-5085(17)36720.
    PubMed     Text format     Abstract available


    November 2017
  24. LIU CJ, Chuang WL, Sheen IS, Wang HY, et al
    Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected with HBV.
    Gastroenterology. 2017 Nov 21. pii: S0016-5085(17)36369.
    PubMed     Text format     Abstract available


  25. SHERMAN KE, Shah VH
    Viral Hepatitis: Knowledge and Treatments for HBV/HCV and Associated Transplantation and Neoplasia.
    Gastroenterology. 2017 Nov 14. pii: S0016-5085(17)36348.
    PubMed     Text format    


  26. DIETZ J, Susser S, Vermehren J, Peiffer KH, et al
    Patterns of Resistance-associated Substitutions in Patients With Chronic HCV Infection Following Treatment with Direct-acting Antivirals.
    Gastroenterology. 2017 Nov 13. pii: S0016-5085(17)36353.
    PubMed     Text format     Abstract available


  27. DEBES JD, van Tilborg M, Groothuismink ZMA, Hansen BE, et al
    Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-acting Antivirals.
    Gastroenterology. 2017 Nov 1. pii: S0016-5085(17)36295.
    PubMed     Text format     Abstract available


    October 2017
  28. RATTAY T, Dumont P, Heinzow HS, Hutton DW, et al
    Cost-effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
    Gastroenterology. 2017 Oct 23. pii: S0016-5085(17)36275.
    PubMed     Text format     Abstract available


  29. JOHN M, Metwally M, Mangia A, Romero-Gomez M, et al
    TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C.
    Gastroenterology. 2017 Oct 6. pii: S0016-5085(17)36134.
    PubMed     Text format    


  30. MONDELLI MU
    Liver MAIT Cells in Hepatitis C: Pathogenetic Role or Innocent Bystanders?
    Gastroenterology. 2017 Oct 4. pii: S0016-5085(17)36186.
    PubMed     Text format    


    September 2017
  31. CHILDS-KEAN LM, Hong J
    Detectable Viremia at the End of Treatment With Direct-Acting Antivirals Can Be Associated With Subsequent Clinical Cure in Patients With Chronic Hepatitis C: A Case Series.
    Gastroenterology. 2017 Sep 4. pii: S0016-5085(17)35912.
    PubMed     Text format    


    August 2017
  32. MAAN R, Feld JJ
    Risk for hepatocellular carcinoma after HCV antiviral therapy with direct-acting antivirals: case closed?
    Gastroenterology. 2017 Aug 31. pii: S0016-5085(17)36085.
    PubMed     Text format    


  33. YU ML
    Resistance-Associated Substitutions in Short Duration of Interferon-Free Direct-Acting Antivirals for Hepatitis C.
    Gastroenterology. 2017 Aug 3. pii: S0016-5085(17)35886.
    PubMed     Text format    


  34. BOLTE FJ, O'Keefe AC, Webb LM, Serti E, et al
    Intra-hepatic Depletion of Mucosal Associated Invariant T cells in Hepatitis C Virus-induced Liver Inflammation.
    Gastroenterology. 2017 Aug 2. pii: S0016-5085(17)35975.
    PubMed     Text format     Abstract available


    July 2017
  35. MISHRA P, Florian J, Peter J, Vainorius M, et al
    Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals.
    Gastroenterology. 2017 Jul 27. pii: S0016-5085(17)35956.
    PubMed     Text format    


  36. LENS S, Alvarado E, Marino Z, Londono MC, et al
    Effects of All-oral Anti-viral Therapy on HVPG and Systemic Hemodynamics in Patients with Hepatitis C Virus-associated Cirrhosis.
    Gastroenterology. 2017 Jul 19. pii: S0016-5085(17)35922.
    PubMed     Text format     Abstract available


    June 2017
  37. KANWAL F, Kramer J, Asch SM, Chayanupatkul M, et al
    Risk of Hepatocellular Cancer in HCV Patients Treated with Direct Acting Antiviral Agents.
    Gastroenterology. 2017 Jun 19. pii: S0016-5085(17)35797.
    PubMed     Text format     Abstract available


  38. ENOMOTO M, Murakami Y, Kawada N
    Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction?
    Gastroenterology. 2017 Jun 2. pii: S0016-5085(17)35638.
    PubMed     Text format    


  39. DE MARCO L, Pellicano R
    When to Search for Occult Infection After Eradication of Hepatitis C?
    Gastroenterology. 2017 Jun 2. pii: S0016-5085(17)35601.
    PubMed     Text format    


    May 2017
  40. KANWAL F, Bacon BR, Beste LA, Brill JV, et al
    Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group.
    Gastroenterology. 2017;152:1588-1598.
    PubMed     Text format    


  41. SINGH S, Muir AJ, Dieterich DT, Falck-Ytter YT, et al
    American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.
    Gastroenterology. 2017;152:1544-1577.
    PubMed     Text format     Abstract available


    April 2017
  42. LAIDLAW SM, Marukian S, Gilmore RH, Cashman SB, et al
    Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent from Interferons.
    Gastroenterology. 2017 Apr 26. pii: S0016-5085(17)35530.
    PubMed     Text format     Abstract available


  43. JACOBSON IM, Lawitz E, Gane EJ, Willems BE, et al
    Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
    Gastroenterology. 2017 Apr 5. pii: S0016-5085(17)35399.
    PubMed     Text format     Abstract available


    March 2017
  44. JACOBSON IM, Lim JK, Fried MW
    AGA Institute Clinical Practice Update: Care of Patients Who Have Achieved a Sustained Virologic Response (SVR) Following Antiviral Therapy for Chronic Hepatitis C Infection.
    Gastroenterology. 2017 Mar 23. pii: S0016-5085(17)30327.
    PubMed     Text format     Abstract available


  45. MISHRA P, Chen M
    Direct-Acting Antivirals for Chronic Hepatitis C: Can Drug Properties Signal Potential for Liver Injury?
    Gastroenterology. 2017 Mar 18. pii: S0016-5085(17)30295.
    PubMed     Text format    


  46. SAADOUN D, Pol S, Ferfar Y, Alric L, et al
    Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia Vasculitis.
    Gastroenterology. 2017 Mar 10. pii: S0016-5085(17)30269.
    PubMed     Text format     Abstract available


  47. COMARMOND C, Garrido M, Pol S, Desbois AC, et al
    Direct-acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-induced Cryoglobulinemia Vasculitis.
    Gastroenterology. 2017 Mar 5. pii: S0016-5085(17)30235.
    PubMed     Text format     Abstract available


    February 2017
  48. AGHEMO A, Colombo M
    Response-Guided Duration of Directly Acting Antiviral Therapy for Chronic Hepatitis C: Back to the Future?
    Gastroenterology. 2017 Feb 27. pii: S0016-5085(17)30205.
    PubMed     Text format    


  49. JACOBSON IM, Lawitz E, Kwo PY, Hezode C, et al
    Safety and Efficacy of Elbasvir/Grazoprevir in Patients with Hepatitis C Virus Infection and Compensated Cirrhosis: an Integrated Analysis.
    Gastroenterology. 2017 Feb 10. pii: S0016-5085(17)30150.
    PubMed     Text format     Abstract available


  50. MATSUURA K, Sawai H, Ikeo K, Ogawa S, et al
    Genome-wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.
    Gastroenterology. 2017 Feb 2. pii: S0016-5085(17)30130.
    PubMed     Text format     Abstract available


  51. RAVI S, Axley P, Jones D, Kodali S, et al
    Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis.
    Gastroenterology. 2017 Feb 1. pii: S0016-5085(16)35535.
    PubMed     Text format    


    January 2017
  52. GANE EJ, Hyland RH, Yang Y, Svarovskaia E, et al
    Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
    Gastroenterology. 2017 Jan 27. pii: S0016-5085(17)30074.
    PubMed     Text format     Abstract available


  53. GOLDBERG D, Ditah IC, Saeian K, Lalehzari M, et al
    Changes in the Prevalence of Hepatitis C Virus Infection, Non-alcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients with Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
    Gastroenterology. 2017 Jan 11. pii: S0016-5085(17)30014.
    PubMed     Text format     Abstract available


    December 2016
  54. KOUTSOUDAKIS G, Perez-Del-Pulgar S, Forns X
    Occult Hepatitis C Virus Infection: Are We Digging Too Deep?
    Gastroenterology. 2016 Dec 27. pii: S0016-5085(16)35528.
    PubMed     Text format    


  55. BOSON B, Denolly S, Turlure F, Chamot C, et al
    Daclatasvir Prevents Hepatitis C Virus by Blocking Transfer of Viral Genome to Assembly Sites.
    Gastroenterology. 2016 Dec 5. pii: S0016-5085(16)35447.
    PubMed     Text format     Abstract available


    November 2016
  56. LI F, Kaffenberger B, Hart PA
    An Unusual Rash During Evaluation for Chronic Pancreatitis.
    Gastroenterology. 2016 Nov 25. pii: S0016-5085(16)34961.
    PubMed     Text format    


  57. COLPITTS CC, Baumert TF
    SMAD about HCV cell entry and pathogenesis of liver disease.
    Gastroenterology. 2016 Nov 23. pii: S0016-5085(16)35398.
    PubMed     Text format    


  58. DONNELLY MC, Imlach SN, Abravanel F, Ramalingam S, et al
    Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient.
    Gastroenterology. 2016 Nov 21. pii: S0016-5085(16)34895.
    PubMed     Text format    


  59. ELMASRY S, Wadhwa S, Bang BR, Cook L, et al
    Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
    Gastroenterology. 2016 Nov 9. pii: S0016-5085(16)35323.
    PubMed     Text format     Abstract available


  60. WANG W, Hakim MS, Nair VP, de Ruiter PE, et al
    Distinct Antiviral Potency of Sofosbuvir against Hepatitis C and E Viruses.
    Gastroenterology. 2016 Nov 1. pii: S0016-5085(16)35194.
    PubMed     Text format    


    October 2016
  61. KOMATSU TE, Boyd S, Sherwat A, Tracy L, et al
    Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
    Gastroenterology. 2016 Oct 20. pii: S0016-5085(16)35241.
    PubMed     Text format     Abstract available


  62. LIANG TJ
    Hepatitis C Virus: from Obscurity to the Lasker.
    Gastroenterology. 2016 Oct 17. pii: S0016-5085(16)35233.
    PubMed     Text format    


  63. KWO P, Gane E, Peng CY, Pearlman B, et al
    Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients with Chronic Hepatitis C Infection.
    Gastroenterology. 2016 Oct 5. pii: S0016-5085(16)35170.
    PubMed     Text format     Abstract available


  64. AGHEMO A, Buti M
    Hepatitis C Therapy: Game Over!
    Gastroenterology. 2016 Oct 1. pii: S0016-5085(16)35131.
    PubMed     Text format    


    September 2016
  65. ZHANG F, Sodroski C, Cha H, Li Q, et al
    Infection of Hepatocytes with HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Upregulating SMAD6 and SMAD7.
    Gastroenterology. 2016 Sep 29. pii: S0016-5085(16)35128.
    PubMed     Text format     Abstract available


  66. NAHON P, Bourcier V, Layese R, Audureau E, et al
    Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
    Gastroenterology. 2016 Sep 15. pii: S0016-5085(16)35070.
    PubMed     Text format     Abstract available


    August 2016
  67. PAWLOTSKY JM
    Hepatitis C Drugs: Is Next Generation the Last Generation?
    Gastroenterology. 2016 Aug 30. pii: S0016-5085(16)34985.
    PubMed     Text format    


  68. TERRAULT NA, Zeuzem S, Di Bisceglie AM, Lim JK, et al
    Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated of Sustained Virologic Response.
    Gastroenterology. 2016 Aug 23. pii: S0016-5085(16)34927.
    PubMed     Text format     Abstract available


    July 2016
  69. LAWITZ E, Reau N, Hinestrosa F, Rabinovitz M, et al
    Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients with Genotype 1 Hepatitis C Virus Infection in an Open-label, Phase 2 Trial.
    Gastroenterology. 2016 Jul 30. pii: S0016-5085(16)34835.
    PubMed     Text format     Abstract available


  70. GANE E, Kowdley KV, Pound D, Stedman CA, et al
    Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients with HCV Genotype 2, 3, 4, or 6 Infections in an Open-label, Phase 2 Trial.
    Gastroenterology. 2016 Jul 30. pii: S0016-5085(16)34834.
    PubMed     Text format     Abstract available


  71. AFDHAL NH, Serfaty L
    Cohort Studies and Registries in the treatment of HCV; the impact of "real life" effectiveness.
    Gastroenterology. 2016 Jul 22. pii: S0016-5085(16)34820.
    PubMed     Text format    


  72. GANE E, Poordad F, Wang S, Asatryan A, et al
    High Efficacy of ABT-493 and ABT-530 in Patients with HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
    Gastroenterology. 2016 Jul 22. pii: S0016-5085(16)34816.
    PubMed     Text format     Abstract available


  73. RAMIREZ S, Mikkelsen LS, Gottwein JM, Bukh J, et al
    Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.
    Gastroenterology. 2016 Jul 21. pii: S0016-5085(16)34809.
    PubMed     Text format     Abstract available


  74. SHIN JY, Azoulay L, Filion KB
    Statin Use in Patients With Hepatitis C-related Cirrhosis: True Benefit or Immortal Time Bias?
    Gastroenterology. 2016 Jul 1. pii: S0016-5085(16)34434.
    PubMed     Text format    


    June 2016
  75. GAMBATO M, Perez-Del-Pulgar S, Hedskog C, Svarovskia ES, et al
    HCV RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen.
    Gastroenterology. 2016 Jun 30. pii: S0016-5085(16)34697.
    PubMed     Text format     Abstract available


  76. SARRAZIN C, Dvory-Sobol H, Svarovskaia ES, Doehle B, et al
    Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment with Ledipasvir and Sofosbuvir.
    Gastroenterology. 2016 Jun 10. pii: S0016-5085(16)34614.
    PubMed     Text format     Abstract available


  77. IOANNOU GN, Beste LA, Chang MF, Green PK, et al
    Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Healthcare System.
    Gastroenterology. 2016 Jun 4. pii: S0016-5085(16)34575.
    PubMed     Text format     Abstract available


    May 2016
  78. GANE EJ, Schwabe C, Hyland RH, Yang Y, et al
    Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-naive or Previously Treated Patients with HCV Genotype 1 or 3 Infections.
    Gastroenterology. 2016 May 27. pii: S0016-5085(16)34513.
    PubMed     Text format     Abstract available


  79. KLINGE MJ, Borhani AA, Malik SM
    Hepatitis C and Numerous Disappearing Hepatic Nodules: No-dule C It, No-dule Don't.
    Gastroenterology. 2016 May 27. pii: S0016-5085(16)30099.
    PubMed     Text format    


    April 2016
  80. BARRESI L, Ligresti D, Traina M
    A Challenging Diagnosis for a Biliary Stricture.
    Gastroenterology. 2016 Apr 29. pii: S0016-5085(16)00215.
    PubMed     Text format    


  81. PAWLOTSKY JM
    Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.
    Gastroenterology. 2016 Apr 11. pii: S0016-5085(16)30055.
    PubMed     Text format     Abstract available


    March 2016
  82. DI MARCO V, Calvaruso V, Ferraro D, Bavetta MG, et al
    Effects of Viral Eradication in Patients with HCV and Cirrhosis Differ With Stage of Portal Hypertension.
    Gastroenterology. 2016 Mar 31. pii: S0016-5085(16)30049.
    PubMed     Text format     Abstract available


  83. AGHEMO A, Colombo M
    No Time for Bullies in Hepatitis C Virus Therapy: Genotype 3 Conquered?
    Gastroenterology. 2016 Mar 24. pii: S0016-5085(16)00378.
    PubMed     Text format    


  84. POCKROS PJ, Reddy KR, Mantry PS, Cohen E, et al
    Efficacy of Direct-acting Antiviral Combination for Patients with HCV Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
    Gastroenterology. 2016 Mar 11. pii: S0016-5085(16)00326.
    PubMed     Text format     Abstract available


    February 2016
  85. YOUNOSSI Z, Park H, Henry L, Adeyemi A, et al
    Extra-Hepatic Manifestations of Hepatitis C-a Meta-Analysis of Prevalence, Quality of Life, and Economic Burden.
    Gastroenterology. 2016 Feb 25. pii: S0016-5085(16)00230.
    PubMed     Text format     Abstract available


  86. SERFATY L
    Clinical implications of concomitant alcohol use, obesity and viral hepatitis.
    Gastroenterology. 2016 Feb 9. pii: S0016-5085(16)00139.
    PubMed     Text format    


  87. HASSAN T, Khan F, Kyprianou A
    A Not So Benign Abdomen!
    Gastroenterology. 2016;150:e1-2.
    PubMed     Text format    


    January 2016
  88. XIA Y, Stadler D, Lucifora J, Reisinger F, et al
    Interferon-gamma and Tumor Necrosis Factor-alpha Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis.
    Gastroenterology. 2016;150:194-205.
    PubMed     Text format     Abstract available


    November 2015
  89. RAZIORROUH B, Sacher K, Tawar RG, Emmerich F, et al
    Virus-specific CD4+ T Cells Have Functional and Phenotypic Characteristics of Follicular T-helper Cells in Patients With Acute and Chronic HCV Infections.
    Gastroenterology. 2015 Nov 13. pii: S0016-5085(15)01622.
    PubMed     Text format     Abstract available


    October 2015
  90. WHITE DL, Richardson P, Tayoub N, Davila JA, et al
    The Updated Model: An Adjusted Serum Alpha-Fetoprotein-Based Algorithm for Hepatocellular Carcinoma Detection With Hepatitis C Virus-Related Cirrhosis.
    Gastroenterology. 2015 Oct 28. pii: S0016-5085(15)01435.
    PubMed     Text format    


  91. SULKOWSKI MS, Vargas HE, Di Bisceglie AM, Kuo PA, et al
    Effectiveness of Simeprevir plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection.
    Gastroenterology. 2015 Oct 21. pii: S0016-5085(15)01507.
    PubMed     Text format     Abstract available


  92. MOHANTY A, Tate J, Garcia-Tsao G
    Statins are Associated with a Decreased Risk of Decompensation and Death in Veterans with Hepatitis C-related Compensated Cirrhosis.
    Gastroenterology. 2015 Oct 17. pii: S0016-5085(15)01476.
    PubMed     Text format     Abstract available


    September 2015
  93. BACK DJ, Burger DM
    Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: Potential mechanisms and lessons to be learned.
    Gastroenterology. 2015 Sep 25. pii: S0016-5085(15)01387.
    PubMed     Text format    


  94. FAUVELLE C, Felmlee DJ, Crouchet E, Lee J, et al
    Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies.
    Gastroenterology. 2015 Sep 21. pii: S0016-5085(15)01358.
    PubMed     Text format     Abstract available


  95. PETTA S, Maida M, Macaluso FS, Barbara M, et al
    Hepatitis C Virus Infection is Associated With Increased Cardiovascular Mortality: A Meta-analysis of Observational Studies.
    Gastroenterology. 2015 Sep 16. pii: S0016-5085(15)01322.
    PubMed     Text format     Abstract available


    August 2015
  96. NEGRO F, Forton D, Craxi A, Sulkowski MS, et al
    Extra-hepatic Morbidity and Mortality of Chronic Hepatitis C.
    Gastroenterology. 2015 Aug 25. pii: S0016-5085(15)01203.
    PubMed     Text format     Abstract available


  97. GANE EJ, Hyland RH, An D, Svarovskaia E, et al
    Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection.
    Gastroenterology. 2015 Aug 7. pii: S0016-5085(15)01096.
    PubMed     Text format     Abstract available


  98. BESTE LA, Leipertz SL, Green PK, Dominitz JA, et al
    Trends in the burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US Veterans from 2001-2013.
    Gastroenterology. 2015 Aug 5. pii: S0016-5085(15)01088.
    PubMed     Text format     Abstract available


  99. FOSTER GR, Pianko S, Brown A, Forton D, et al
    Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-alfa in Patients With HCV Genotype 3 Infection and Treatment-Experienced Patients with Cirrhosis and HCV Genotype 2 Infection.
    Gastroenterology. 2015 Aug 3. pii: S0016-5085(15)01069.
    PubMed     Text format     Abstract available


  100. HSU YC, Wu CY
    Reply.
    Gastroenterology. 2015;149:501-2.
    PubMed     Text format    


    July 2015
  101. LAWITZ E, Makara M, Akarca US, Thuluvath PJ, et al
    Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-label Study of Patients With Genotype 1b Chronic Hepatitis C Virus, With and Without Cirrhosis.
    Gastroenterology. 2015 Jul 10. pii: S0016-5085(15)00936.
    PubMed     Text format     Abstract available


    June 2015
  102. AGHEMO A, Colombo M
    Will the Benefits of Treatment for Chronic Hepatitis C Be Retained in the Interferon-free Era?
    Gastroenterology. 2015 Jun 27. pii: S0016-5085(15)00894.
    PubMed     Text format    


    May 2015
  103. MONDELLI MU
    Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C.
    Gastroenterology. 2015 May 26. pii: S0016-5085(15)00720.
    PubMed     Text format    


  104. CHARLTON M, Everson GT, Flamm SL, Kumar P, et al
    Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease.
    Gastroenterology. 2015 May 15. pii: S0016-5085(15)00682.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: